Adaptimmune Therapeutics (NASDAQ:ADAP) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research note issued to investors on Friday. The brokerage set a “buy” rating on the biotechnology company’s stock.

Separately, Mizuho lowered their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating on the stock in a report on Wednesday, November 27th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $2.79.

Adaptimmune Therapeutics Stock Performance

NASDAQ:ADAP opened at $0.28 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. The firm has a market cap of $71.65 million, a price-to-earnings ratio of -1.27 and a beta of 2.52. The firm’s fifty day moving average price is $0.55 and its 200 day moving average price is $0.71. Adaptimmune Therapeutics has a 1-year low of $0.26 and a 1-year high of $1.65.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ADAP. Invesco Ltd. boosted its position in shares of Adaptimmune Therapeutics by 82.0% during the 4th quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 28,526 shares in the last quarter. Two Sigma Advisers LP boosted its stake in shares of Adaptimmune Therapeutics by 492.0% during the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 58,787 shares in the last quarter. Two Sigma Investments LP raised its stake in shares of Adaptimmune Therapeutics by 33.5% during the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock worth $41,000 after buying an additional 19,146 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Adaptimmune Therapeutics during the third quarter worth about $95,000. Finally, Virtu Financial LLC raised its position in Adaptimmune Therapeutics by 27.5% in the third quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 21,769 shares during the period. Hedge funds and other institutional investors own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.